Clinical Trials Logo
  1. Home
  2. Leptomeningeal Metastases
  3. NCT03520504

Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases

Leptomeningeal Metastases Clinical Trial

Official title:
A Phase Ib Study With Dose Expansion Cohort of Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors

Clinical Trial Summary

The purpose of this study is to find the safest and most effective dose for delivering proton beam to the space containing CSF, brain, and spinal cord, in treating leptomeningeal metastases. The researchers think that using proton beam radiation to treat the space containing CSF, brain, and spinal cord, instead of treating only the areas where the metastasized tumor cells are causing symptoms, would improve the treatment of this disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03520504
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase Phase 1
Start date April 26, 2018
Completion date December 22, 2022
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01438021 - Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease N/A
Completed NCT02616393 - Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases Phase 2
Completed NCT03101579 - Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer Phase 1
Active, not recruiting NCT03719768 - Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Phase 1
Terminated NCT00005812 - Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma Phase 2
Terminated NCT03661424 - BATs in Patients With Breast Cancer and Leptomeningeal Metastases Phase 1
Active, not recruiting NCT05289908 - Intrathecal Pemetrexed for Leptomeningeal Metastasis Phase 1/Phase 2
Recruiting NCT05184816 - A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis Phase 1
Not yet recruiting NCT03613181 - ANG1005 in Leptomeningeal Disease From Breast Cancer Phase 3
Terminated NCT03275402 - 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Phase 2/Phase 3
Completed NCT01645839 - Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer Phase 3
Completed NCT00992602 - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Phase 2
Completed NCT00005811 - Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Phase 2
Active, not recruiting NCT04343573 - Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors Phase 2